These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 38419274)
21. Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study. Kochhar GS; Desai A; Farraye FA; Cross RK; El-Hachem S; Dulai PS; Regueiro M Aliment Pharmacol Ther; 2023 Aug; 58(3):297-308. PubMed ID: 37300328 [TBL] [Abstract][Full Text] [Related]
22. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA; J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN. Cohen S; Rolandsdotter H; Kolho KL; Turner D; Tzivinikos C; Bramuzzo M; Pujol-Muncunill G; Scarallo L; Urlep D; Rinawi F; Granot M; Kang B; Longueville Y; Rodríguez-Belvís MV; Weintraub Y; Navas-López VM; Yerushalmy-Feler A Paediatr Drugs; 2024 Sep; 26(5):609-617. PubMed ID: 38780740 [TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review. Irving PM; Hur P; Gautam R; Guo X; Vermeire S J Manag Care Spec Pharm; 2024 Sep; 30(9):1026-1040. PubMed ID: 39213145 [TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Amiot A; Filippi J; Abitbol V; Cadiot G; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Pariente B; Fumery M; Aliment Pharmacol Ther; 2020 Jun; 51(11):1039-1046. PubMed ID: 32291786 [TBL] [Abstract][Full Text] [Related]
28. Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis. Adimadhyam S; Lewis JD; Simon AL; Wolfe AE; Smith S; Hou L; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett L; Haynes K; Burris J; Dorand JE; Long MD; Kappelman MD Inflamm Bowel Dis; 2024 Apr; 30(4):554-562. PubMed ID: 37358904 [TBL] [Abstract][Full Text] [Related]
29. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR Inflamm Bowel Dis; 2024 Oct; 30(10):1707-1713. PubMed ID: 37843044 [TBL] [Abstract][Full Text] [Related]
30. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421 [TBL] [Abstract][Full Text] [Related]
31. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S Aliment Pharmacol Ther; 2019 Nov; 50(10):1068-1076. PubMed ID: 31599001 [TBL] [Abstract][Full Text] [Related]
32. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488 [TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164 [TBL] [Abstract][Full Text] [Related]
35. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Meyer A; Fumery M; Peyrin-Biroulet L; Filippi J; Altwegg R; Bouhnik Y; Serrero M; Laharie D; Roblin X; Nachury M; Abitbol V; Cadiot G; Nancey S; Allez M; Gilletta C; Vuitton L; Savoye G; Nahon S; Bourrier A; Buisson A; Bouguen G; Bourreille A; Viennot S; Carbonnel F; Amiot A Scand J Gastroenterol; 2022 Dec; 57(12):1454-1462. PubMed ID: 35819361 [TBL] [Abstract][Full Text] [Related]
36. Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study. Parra-Izquierdo V; Frías-Ordoñez JS; Juliao-Baños F; Cuadros C; Romero Sanchez C; Flórez-Sarmiento C Gastroenterol Hepatol; 2024; 47(6):582-590. PubMed ID: 37806342 [TBL] [Abstract][Full Text] [Related]
37. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience. Parra-Izquierdo V; Frías-Ordoñez JS; Márquez JR; Juliao-Baños F; Galindo P; Cuadros C; Rojas C; Rojas N; Ardila O; Tovar-Fierro G; García-Duperly R; Vargas M; Flórez-Sarmiento C Gastroenterol Hepatol; 2023; 46(7):512-521. PubMed ID: 36372256 [TBL] [Abstract][Full Text] [Related]
38. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181 [No Abstract] [Full Text] [Related]
39. Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study. Molander P; Kosunen M; Eronen H; Tillonen J; Käräjämäki A; Heikkinen M; Punkkinen J; Mattila R; Toppila I; Hölsä O; Kalpala K; Henrohn D; Af Björkesten CG Scand J Gastroenterol; 2024 Apr; 59(4):425-432. PubMed ID: 38156792 [TBL] [Abstract][Full Text] [Related]
40. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]